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Thermally Triggered Theranostics for Pancreatic Cancer
Introduction
• Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent
epithelial, exocrine pancreatic cancer, which shows for more than 80% of
the malignant neoplasms of the pancreas. The extracellular section of
PDAC is normally a dense stromal, called desmoplastic, which has been
demonstrated to affect drug delivery and reaction to gemcitabine in
preclinical models. Thus, it is highly demanded to increase the efficacy of
this treatment as well as exploring alternative therapies.
• Iron oxide-gold as hybrid nanoparticles (HNPs) have recently been the
focus of a number of investigations and are becoming increasingly
applicable in biomedicine (Fig. 1).
Figure 1. Schematic diagram of gold-iron oxide core-shell nanoparticle presenting electrostatic charges
within each layer.
• By using both iron oxide and gold within one drug delivery vehicle, a
multifaceted and stable system can be fabricated. This takes the
advantage of the surface chemistry and SPR of the gold whilst holding the
magnetic character of the iron oxide, offering imaging, heating and drug
carrier potentials.
• Bisnaphthalimide derivatives have exhibited exciting potential as
chemotherapeutic agents, which is due to their interactions with DNA by
intercalation (Fig. 2)
Figure 2. Basic bisnaphthalimide chemical structure.
• Arginine-glycine-aspartic acid (RGD) peptides have high affinity to integrin
αvβ3, which plays a significant role in tumour angiogenesis. This peptide is
a receptor for the extracellular matrix proteins with the exposed RGD
tripeptide sequence and expressed on many different types of cancer as
for pancreatic cancer.
• Successful fabrication of the iron oxide core and subsequent coating steps to
achieve the HNPs was evident from the TEM (Fig. 3A), UV-Vis (Fig. 3B) and zeta
potential measurement (Fig. 3C).
Figure 3. Physicochemical characteriation of the nanoparticle synthesis steps using A) transmission electrion microscopy,
B) UV-Vis spectroscopy and C) zeta potential measurement.
• The HNPs ability to act as localised nanoheaters after laser irradiation (Fig. 4A) and
MRI contrast agents (Fig. 4B) was assessed whilst suspended in an agar phantom.
The data suggested that the HNPs possessed similar contrast-ability to commercially
available Feridex® and were capable of temperature increases over 30 degrees.
Figure 4. Physical properties of HNPs including A) ability to act as a nano heater after laser irradiation (1064 nm, Nd:YAG),
B) ability to act as a T2 contrast agent and C) ability to electrostatically bind charged drug molecules onto the surface.
• The ability of drug molecules to electrostatically attach onto the HNP surface as
investigated and measured by HPLC (Fig. 4C). The data suggested that increasing
the number of amine groups in the polyamine chain of the bisnaphthalimido drugs
resulted in greater conjugation and stability (Fig. 5 A1&A2). The presence of a thiol
resulted in dative covalent binding onto the gold surface and these molecules were
used as a control.
• Drug release profiles were determined over 14 days to evaluate the strength of
binding of the bisnaphthimido drugs of varied charges (Fig. 5 B1-3). The data
showed that increasing the positive charge in the polyamine backbone due to the
presence of primary amine groups resulted in increased binding. The drug with no
charge did not bind and was 100% released immediately. With 4 charges in the
backbone the drug was steadily released over the experimental period.
Figure 5. A) Stability testing of formulation over 4 weeks stored as 1) liquid preparation and 2) freeze dried preparation. B)
Drug release profile of birnaphthalimido drugs from HNP surface in cell culture media of 1) 0, 2) 2 and 3) 4 amine charges
in the polyamine backbone.
Results Results
• The formulations cytoxicity was determined using MTT assay and trypan blue exclusion on 
human pancreatic adenocarcinoma (BxPC-3) cells (Fig. 6A). The data showed a significant 
reduction in IC50 after drug conjugation onto HNPs compared with free drug. RGD was 
added onto the formulation to confer a targeting effect, however, this did not have any 
significant effect on the IC50 values observed (Fig. 6B) Cellular uptake studies also showed 
that increased drug content was achievable after conjugation (Fig. 6D), after conjugation of 
the RGD s significant increase in drug was achieved in the PEGylated formulations.
Figure 6. Cytotoxicity testing of novel formulations on BxPC-3 cells measured by MTT assay and trypan blue exclusion both A)
without and B) with attachement of a cyclic RGD targeting peptide. Cellular uptake of drug molecules measured by high performance
liquid chromatography both C) without and D) with the presence of a cyclic RGD targeting peptide.
• Cellular morphology after exposure to the free drugs (4 charges) and HNP formulations (4
charges) was assessed after 4 h using AFM. The images show that after this sort time the
cells exposed to the free drug (Fig. 7B) or uncoated HNPs (Fig. 7C) do not exhibit any
morphological changes and look healthy, whereas the cells exposed to the novel
formulations look to be undegoing cellular breakdown as a result of the increased
cytotoxicity (Fig. 7D).
Figure 7. AFM topographical analysis of fixed BxPC-3 cells after exposure to A) cell culture media (control), B) free drug (4 charges),
C) uncoated HNPs and D) HNP-drug (4 charges) for 4h.
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Conclusion
This work highlights the multifunctional nature of hybrid nanoparticles for use in image guided
triggered drug delivery. Further work is on-going to evaluate the in viivo potential of these
systems in pancreatic cancer xenograft models.
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• Laser irradiation of HNPs (50 μgmL-1) in vitro 
over 60 sec showed a temperature rise of 9 
degrees (Fig. 8A). 4 h after irradiation the 
cells were fixed and imaged for topography 
showing no structural damage (Fig. 8B). This 
suggests these particles could be exploited in 
thermally triggered drug release. The 
threshold energy required drug in vitro is 
being investigated.
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Figure 8. A) Laser irradiation of HNPs in vitro (50 μgmL-1) and B) 
imaging of cellular morphology using AFM 4 h post irradiation.
